Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Egfr Mutant ◽

Inhibitor Resistance ◽

Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-11-1171 ◽

2012 ◽

Vol 18 (6) ◽

pp. 1663-1671 ◽

Cited By ~ 49

Author(s):

Wei Wang ◽

Qi Li ◽

Shinji Takeuchi ◽

Tadaaki Yamada ◽

Hitomi Koizumi ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Egfr Mutant ◽

Inhibitor Resistance ◽

Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells

Clinical Cancer Research ◽

10.1158/1078-0432.12aacriaslc-b21 ◽

2012 ◽

Vol 18 (3 Supplement) ◽

pp. B21-B21

Author(s):

Takayuki Nakagawa ◽

Shinji Takeuchi ◽

Tadaaki Yamada ◽

Kenji Kita ◽

Seiji Yano

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Tyrosine Kinase ◽

Cancer Cells ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Kinase Inhibitor ◽

Egfr Mutant ◽

Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor

Oncogene ◽

10.1038/sj.onc.1204531 ◽

2001 ◽

Vol 20 (29) ◽

pp. 3845-3856 ◽

Cited By ~ 46

Author(s):

Francesco Frasca ◽

Paolo Vigneri ◽

Veronica Vella ◽

Riccardo Vigneri ◽

Jean Y J Wang

Keyword(s):

Thyroid Cancer ◽

Growth Factor ◽

Tyrosine Kinase ◽

Cancer Cell ◽

Kinase Inhibitor ◽

Thyroid Cancer Cell ◽

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Mutant

Uncovering tyrosine kinase inhibitor resistance mutations in EGFR mutant lung adenocarcinoma using whole-exome sequencing

10.5353/th_991044168862503414 ◽

2019 ◽

Author(s):

Xuyuan Gao

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Exome Sequencing ◽

Whole Exome Sequencing ◽

Kinase Inhibitor ◽

Resistance Mutations ◽

Whole Exome ◽

Egfr Mutant ◽

Inhibitor Resistance

Abstract 748: The glucose metabolism targeting therapies and withaferin A eliminate epidermal growth factor tyrosine kinase inhibitor-induced drug-tolerant persisters in non-small lung cancer cells

10.1158/1538-7445.am2015-748 ◽

2015 ◽

Author(s):

Kei Kunimasa ◽

Tatsuya Nagano ◽

Yohei Shimono ◽

Shuntaro Tokunaga ◽

Daisuke Tamura ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Glucose Metabolism ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Cancer Cells ◽

Kinase Inhibitor ◽

Withaferin A ◽

Epidermal Growth

Abstract B57: MUC3A induces PD-L1 and reduces tyrosine kinase inhibitor effects functions in EGFR-mutant non-small cell lung cancer

10.1158/2326-6074.tumimm19-b57 ◽

2020 ◽

Author(s):

Yan Gong ◽

Yuan Luo ◽

Shan Peng ◽

Shijing Ma ◽

Yingming Sun ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Mutant

Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor AZD2171 and Fractionated Radiotherapy in Mouse Models of Lung Cancer

Cancer Research ◽

10.1158/0008-5472.can-06-2414 ◽

2006 ◽

Vol 66 (23) ◽

pp. 11409-11415 ◽

Cited By ~ 37

Author(s):

Carolyn Cao ◽

Jeffrey M. Albert ◽

Ling Geng ◽

Percy S. Ivy ◽

Alan Sandler ◽

...

Keyword(s):

Lung Cancer ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinase ◽

Mouse Models ◽

Kinase Inhibitor ◽

Vascular Endothelial ◽

Fractionated Radiotherapy ◽

Endothelial Growth Factor

Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer

Frontiers in Oncology ◽

10.3389/fonc.2017.00288 ◽

2017 ◽

Vol 7 ◽

Cited By ~ 2

Author(s):

Hongjian Li ◽

Christy Wing-Sum Tong ◽

Yee Leung ◽

Man-Hon Wong ◽

Kenneth Kin-Wah To ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Epidermal Growth ◽

Approved Drugs

1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1598 ◽

2020 ◽

Vol 31 ◽

pp. S829-S830

Author(s):

E. Felip ◽

V. Minotti ◽

R. Soo ◽

J. Wolf ◽

B. Solomon ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Met Inhibitor ◽

Egfr Mutant